- Technologies Impacting.
- New High Growth Revenue Sources & Global Market Size.
- Top Market Players & Geographic Overview.
Technologies impacting Clinical microbiology market
• Polymerase Chain Reaction (PCR)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Microarraysand 34 more
New High Growth Revenue Sources & Global market size-
New High Growth Revenue Sources for Clinical microbiology market
• Molecular Quality Controls Market - 0.17BN 10.2%
• Mycoplasma Testing Market - 0.69BN 9.7%
• Laboratory Proficiency Testing Market - 0.85BN 6.6%and 18 more
According to the new market research report Clinical Microbiology Market is estimated to be $3.9 billion in 2020 and projected to reach $5.3 billion by 2025, at a CAGR of 6.5%.
Leading Players & Growth Strategies -
The major players operating in the microbiology testing/clinical microbiology market are bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.
For More Details, Download PDF Brochure
Geographic Overview -
North America is expected to account for the largest share of the global clinical microbiology market in 2018 due to easy accessibility and high adoption of advanced diagnostic techniques, technological advancements in microbial testing techniques, rising geriatric population, and growing public-private funding to support microbiology-based research in the region.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.